Start here if you're new
what it is
Karyopharm sells an oral cancer drug for certain blood cancers, and almost everything rides on it.
how it gets paid
Last year Karyopharm Therap made $146M in revenue. multiple myeloma combo was the main engine at $80M, or 55% of sales.
why it's growing
Revenue grew 0.6% last year. Revenue of $112M mattered most. It was up 154% from a year earlier.
what just happened
Revenue hit $112M, but the company still lost $10.93 a share.
At a glance
C balance sheet — red flag territory — real financial stress
60/100 earnings predictability — reasonably predictable
-$22.64 fy2024 eps est
$145M fy2024 rev est
62.1% operating margin
xvary composite: 22/100 — weak
What they do
Karyopharm sells an oral cancer drug for certain blood cancers, and almost everything rides on it.
XPOVIO is the only real engine here. XPO1 inhibitor → protein export blocker → it traps cancer signals inside the cell. This is not a many-drug story; it becomes one only if another product line brings real sales or margins climb above -62.1%.
How they make money
$146M
annual revenue · their business grew +0.6% last year
multiple myeloma combo
$80M
relapsed/refractory multiple myeloma
$38M
diffuse large b-cell lymphoma
$18M
other product revenue
$10M
The products that matter
commercial oncology drug
XPOVIO
$139M · about 95% of revenue
this is the business. at about $139M of a $146M revenue base, XPOVIO is carrying nearly all of the commercial load.
core asset
non-core revenue
Other revenue
$7M · about 5% of revenue
the rest of the income statement is only $7M. in plain English: there is no second engine here yet.
small support
balance sheet capacity
cash + financing runway
$146M cash vs. $183M debt
for a company losing money, cash is time. when debt is $183M and market value is about $144M, financing risk stops being a footnote and becomes part of the product set.
the real constraint
Key numbers
$146M
annual revenue
That is tiny next to $183M of debt, so each sales miss hits hard.
62.1%
operating margin
You lose 62 cents on every sales dollar before the final line.
$183M
long-term debt
The debt stack is bigger than the market cap, which leaves little room for error.
1.5
beta
The stock moves about 50% more than the market, so bad news tends to hit harder.
Financial health
C
strength
- balance sheet grade C — very weak — significant financial distress
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $183M (56% of capital)
C — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for KPTI right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $112M, but the company still lost $10.93 a share.
Revenue was up 154% from a year earlier. Gross margin was 9.93%, which means most of the revenue still went to costs before overhead.
$112.0M
revenue
-$10.93
eps
9.93%
gross margin
the number that mattered
Revenue of $112M mattered most. It was up 154% from a year earlier, but the company still lost $10.93 a share.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is cash pressure around a one-drug business. if XPOVIO slips or losses stay deep, financing becomes the story fast.
med
XPOVIO underperforms
About $139M of $146M revenue comes from U.S. XPOVIO sales. If that product weakens, you do not have another revenue stream ready to catch the fall.
This risk touches roughly 95% of current revenue.
med
financing pressure
Cash is about $146M. Long-term debt is $183M. Market value is about $144M. That mix makes dilution, refinancing stress, or both a live issue if losses continue.
Debt already exceeds the equity market cap, which tells you how thin the cushion is.
med
the market stops paying for optionality
Biotech stocks do not need a disaster to fall. Sometimes investors just stop assigning value to pipeline hope when the core business is flat and the balance sheet is weak.
With price stability at 5/100 and beta at 1.5, multiple compression tends to look violent.
If flat revenue, deep losses, and financing pressure land at the same time, the stock does not need a complicated bear case. It already has a simple one.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
U.S. XPOVIO sales concentration
About 95% of revenue comes from one product. If that share drops because something else grows, good. If it drops because XPOVIO weakens, that is a different story.
risk
cash versus debt
Cash is about $146M. Long-term debt is $183M. Watch that spread before you watch the daily chart.
calendar
next results update
Use the next report to check two things: whether sales are still flat and whether management bought more time without punishing shareholders.
trend
price behavior
A 5/100 price stability score and 1.5 beta tell you this name trades like a catalyst stock. Expect sharper moves than the average healthcare name.
Analyst rankings
short-term outlook
mixed
target data is thin here. in human-speak, the street does not have a clean shared view.
risk profile
volatile
beta is 1.5 and price stability is 5/100. you should expect bigger swings than a normal healthcare stock.
chart momentum
catalyst-driven
this chart follows funding pressure and product headlines more than smooth technical patterns.
earnings predictability
60/100
that is middling. you have some visibility, but not the kind that lets you relax.
source: institutional data
Institutional activity
institutional ownership data for KPTI is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive